The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

Juno Therapeutics Announces Patent Litigation Settlement

06-Apr-2015 | Source : Juno Therapeutics Inc | Visits : 6293
SEATTLE - Juno Therapeutics Inc. today announced in a press release that it entered into a settlement agreement to resolve litigation with the Trustees of the University of Pennsylvania ("Penn") and Novartis Pharmaceuticals Corporation ("Novartis").

Juno became a party to the litigation after it entered into a December 2013 license agreement with St. Jude Children's Research Hospital ("St. Jude"), also a party in the litigation, for patent rights owned by St. Jude. The litigation itself, which began in July 2012 in connection with a contract dispute between St. Jude and Penn, was broadened in March 2013 to include a dispute concerning St. Jude's U.S. Patent No. 8,399,645, titled "Chimeric Receptors with 4-1BB Stimulatory Signaling Domain."

Under the terms of the settlement, Novartis agreed to make payments to Juno including an initial payment of $12.25 million, future milestone payments, and mid-single digit royalties from U.S. net sales of product candidates related to the disputed contract and patent claims, as well as a low double digit percentage of the royalties Novartis pays to Penn for global net sales for those product candidates. Payments received by Juno will be shared with St. Jude under the terms of the license agreement between Juno and St. Jude. The parties also agreed to dismiss all claims in the relevant legal proceedings.

"We are pleased by this settlement, which benefits patients by allowing each party to advance its promising cancer immunotherapies and rewards the investigators on whose insights those developments are based," said Juno CEO, Hans Bishop.

Juno Therapeutics, Inc. ("Juno") is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer. 

Related Articles